The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-epileptic Drugs for Pediatrics Market Research Report 2020

Global Anti-epileptic Drugs for Pediatrics Market Research Report 2020

Publishing Date : Feb, 2020

License Type :
 

Report Code : 1388455

No of Pages : 120

Synopsis
Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

The global Anti-epileptic Drugs for Pediatrics market is valued at 689.5 million US$ in 2020 is expected to reach 940.3 million US$ by the end of 2026, growing at a CAGR of 4.5% during 2021-2026.
This report focuses on Anti-epileptic Drugs for Pediatrics volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Anti-epileptic Drugs for Pediatrics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Anti-epileptic Drugs for Pediatrics market is segmented into
1st generation
2nd generation
3rd generation

Segment by Application
Hospitals
Retail pharmacies
Online pharmacies

Global Anti-epileptic Drugs for Pediatrics Market: Regional Analysis
The Anti-epileptic Drugs for Pediatrics market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Anti-epileptic Drugs for Pediatrics market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Anti-epileptic Drugs for Pediatrics Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Anti-epileptic Drugs for Pediatrics market include:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Index
Table of Contents

1 Anti-epileptic Drugs for Pediatrics Market Overview
1.1 Product Overview and Scope of Anti-epileptic Drugs for Pediatrics
1.2 Anti-epileptic Drugs for Pediatrics Segment by Type
1.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 1st generation
1.2.3 2nd generation
1.2.4 3rd generation
1.3 Anti-epileptic Drugs for Pediatrics Segment by Application
1.3.1 Anti-epileptic Drugs for Pediatrics Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Retail pharmacies
1.3.4 Online pharmacies
1.4 Global Anti-epileptic Drugs for Pediatrics Market Size Estimates and Forecasts
1.4.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2015-2026
1.4.2 Global Anti-epileptic Drugs for Pediatrics Sales 2015-2026
1.4.3 Anti-epileptic Drugs for Pediatrics Market Size by Region: 2020 Versus 2026

2 Global Anti-epileptic Drugs for Pediatrics Market Competition by Manufacturers
2.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2015-2020)
2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2015-2020)
2.3 Global Anti-epileptic Drugs for Pediatrics Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Anti-epileptic Drugs for Pediatrics Manufacturing Sites, Area Served, Product Type
2.5 Anti-epileptic Drugs for Pediatrics Market Competitive Situation and Trends
2.5.1 Anti-epileptic Drugs for Pediatrics Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Anti-epileptic Drugs for Pediatrics Players (Opinion Leaders)

3 Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario by Region
3.1 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country
3.3.1 North America Anti-epileptic Drugs for Pediatrics Sales by Country
3.3.2 North America Anti-epileptic Drugs for Pediatrics Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country
3.4.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Country
3.4.2 Europe Anti-epileptic Drugs for Pediatrics Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Region
3.5.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region
3.5.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country
3.6.1 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country
3.6.2 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country
3.7.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country
3.7.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Anti-epileptic Drugs for Pediatrics Historic Market Analysis by Type
4.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020)
4.2 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type (2015-2020)
4.3 Global Anti-epileptic Drugs for Pediatrics Price Market Share by Type (2015-2020)
4.4 Global Anti-epileptic Drugs for Pediatrics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Anti-epileptic Drugs for Pediatrics Historic Market Analysis by Application
5.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020)
5.2 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application (2015-2020)
5.3 Global Anti-epileptic Drugs for Pediatrics Price by Application (2015-2020)

6 Company Profiles and Key Figures in Anti-epileptic Drugs for Pediatrics Business
6.1 Mylan N.V
6.1.1 Corporation Information
6.1.2 Mylan N.V Description, Business Overview and Total Revenue
6.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Mylan N.V Products Offered
6.1.5 Mylan N.V Recent Development
6.2 Cephalon, Inc
6.2.1 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.2.2 Cephalon, Inc Description, Business Overview and Total Revenue
6.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Cephalon, Inc Products Offered
6.2.5 Cephalon, Inc Recent Development
6.3 GlaxoSmithKline plc
6.3.1 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.3.2 GlaxoSmithKline plc Description, Business Overview and Total Revenue
6.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.3.4 GlaxoSmithKline plc Products Offered
6.3.5 GlaxoSmithKline plc Recent Development
6.4 Janssen Pharmaceuticals
6.4.1 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.4.2 Janssen Pharmaceuticals Description, Business Overview and Total Revenue
6.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Janssen Pharmaceuticals Products Offered
6.4.5 Janssen Pharmaceuticals Recent Development
6.5 Novartis AG
6.5.1 Novartis AG Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.5.2 Novartis AG Description, Business Overview and Total Revenue
6.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Novartis AG Products Offered
6.5.5 Novartis AG Recent Development
6.6 Pfizer, Inc
6.6.1 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.6.2 Pfizer, Inc Description, Business Overview and Total Revenue
6.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Pfizer, Inc Products Offered
6.6.5 Pfizer, Inc Recent Development
6.7 Sanofi S.A
6.6.1 Sanofi S.A Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.6.2 Sanofi S.A Description, Business Overview and Total Revenue
6.6.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Sanofi S.A Products Offered
6.7.5 Sanofi S.A Recent Development
6.8 UCB Pharma Limited
6.8.1 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.8.2 UCB Pharma Limited Description, Business Overview and Total Revenue
6.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.8.4 UCB Pharma Limited Products Offered
6.8.5 UCB Pharma Limited Recent Development
6.9 Sunovion Pharmaceuticals Limited
6.9.1 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.9.2 Sunovion Pharmaceuticals Limited Description, Business Overview and Total Revenue
6.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Sunovion Pharmaceuticals Limited Products Offered
6.9.5 Sunovion Pharmaceuticals Limited Recent Development
6.10 Valeant Pharmaceuticals International, Inc
6.10.1 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.10.2 Valeant Pharmaceuticals International, Inc Description, Business Overview and Total Revenue
6.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Valeant Pharmaceuticals International, Inc Products Offered
6.10.5 Valeant Pharmaceuticals International, Inc Recent Development
6.11 Zogenix
6.11.1 Zogenix Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.11.2 Zogenix Anti-epileptic Drugs for Pediatrics Description, Business Overview and Total Revenue
6.11.3 Zogenix Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Zogenix Products Offered
6.11.5 Zogenix Recent Development
6.12 GW Pharmaceuticals
6.12.1 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.12.2 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Description, Business Overview and Total Revenue
6.12.3 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.12.4 GW Pharmaceuticals Products Offered
6.12.5 GW Pharmaceuticals Recent Development
6.13 Insys
6.13.1 Insys Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.13.2 Insys Anti-epileptic Drugs for Pediatrics Description, Business Overview and Total Revenue
6.13.3 Insys Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.13.4 Insys Products Offered
6.13.5 Insys Recent Development
6.14 Zynerba
6.14.1 Zynerba Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
6.14.2 Zynerba Anti-epileptic Drugs for Pediatrics Description, Business Overview and Total Revenue
6.14.3 Zynerba Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2015-2020)
6.14.4 Zynerba Products Offered
6.14.5 Zynerba Recent Development

7 Anti-epileptic Drugs for Pediatrics Manufacturing Cost Analysis
7.1 Anti-epileptic Drugs for Pediatrics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Anti-epileptic Drugs for Pediatrics
7.4 Anti-epileptic Drugs for Pediatrics Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Anti-epileptic Drugs for Pediatrics Distributors List
8.3 Anti-epileptic Drugs for Pediatrics Customers

9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis

10 Global Market Forecast
10.1 Global Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Anti-epileptic Drugs for Pediatrics by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Anti-epileptic Drugs for Pediatrics by Type (2021-2026)
10.2 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Anti-epileptic Drugs for Pediatrics by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Anti-epileptic Drugs for Pediatrics by Application (2021-2026)
10.3 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Anti-epileptic Drugs for Pediatrics by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Anti-epileptic Drugs for Pediatrics by Region (2021-2026)
10.4 North America Anti-epileptic Drugs for Pediatrics Estimates and Projections (2021-2026)
10.5 Europe Anti-epileptic Drugs for Pediatrics Estimates and Projections (2021-2026)
10.6 Asia Pacific Anti-epileptic Drugs for Pediatrics Estimates and Projections (2021-2026)
10.7 Latin America Anti-epileptic Drugs for Pediatrics Estimates and Projections (2021-2026)
10.8 Middle East and Africa Anti-epileptic Drugs for Pediatrics Estimates and Projections (2021-2026)
11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Comparison by Application: 2020 VS 2026
Table 3. Global Anti-epileptic Drugs for Pediatrics Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. Global Key Anti-epileptic Drugs for Pediatrics Manufacturers Covered in This Study
Table 5. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Manufacturers (2015-2020)
Table 6. Global Anti-epileptic Drugs for Pediatrics Sales Share by Manufacturers (2015-2020)
Table 7. Global Anti-epileptic Drugs for Pediatrics Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Anti-epileptic Drugs for Pediatrics Average Price (USD/Unit) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Anti-epileptic Drugs for Pediatrics Sales Sites and Area Served
Table 11. Manufacturers Anti-epileptic Drugs for Pediatrics Product Types
Table 12. Global Anti-epileptic Drugs for Pediatrics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Anti-epileptic Drugs for Pediatrics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-epileptic Drugs for Pediatrics as of 2019)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Anti-epileptic Drugs for Pediatrics Players
Table 16. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Region (2015-2020)
Table 17. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2015-2020)
Table 18. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) by Region (2015-2020)
Table 19. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2015-2020)
Table 20. North America Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units)
Table 21. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020)
Table 22. North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020)
Table 24. Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units)
Table 25. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020)
Table 26. Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region (2015-2020) (K Units)
Table 29. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2015-2020)
Table 32. Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units)
Table 33. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020)
Table 34. Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units)
Table 37. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020)
Table 40. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Type (2015-2020)
Table 41. Global Anti-epileptic Drugs for Pediatrics Sales Share by Type (2015-2020)
Table 42. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) by Type (2015-2020)
Table 43. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Type (2015-2020)
Table 44. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Type (2015-2020)
Table 45. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Application (2015-2020)
Table 46. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020)
Table 47. Global Anti-epileptic Drugs for Pediatrics Sales Growth Rate by Application (2015-2020)
Table 48. Mylan N.V Anti-epileptic Drugs for Pediatrics Corporation Information
Table 49. Mylan N.V Description and Business Overview
Table 50. Mylan N.V Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 51. Mylan N.V Main Product
Table 52. Mylan N.V Recent Development
Table 53. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Corporation Information
Table 54. Cephalon, Inc Corporation Information
Table 55. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 56. Cephalon, Inc Main Product
Table 57. Cephalon, Inc Recent Development
Table 58. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Corporation Information
Table 59. GlaxoSmithKline plc Corporation Information
Table 60. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 61. GlaxoSmithKline plc Main Product
Table 62. GlaxoSmithKline plc Recent Development
Table 63. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Corporation Information
Table 64. Janssen Pharmaceuticals Corporation Information
Table 65. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 66. Janssen Pharmaceuticals Main Product
Table 67. Janssen Pharmaceuticals Recent Development
Table 68. Novartis AG Anti-epileptic Drugs for Pediatrics Corporation Information
Table 69. Novartis AG Corporation Information
Table 70. Novartis AG Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 71. Novartis AG Main Product
Table 72. Novartis AG Recent Development
Table 73. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Corporation Information
Table 74. Pfizer, Inc Corporation Information
Table 75. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 76. Pfizer, Inc Main Product
Table 77. Pfizer, Inc Recent Development
Table 78. Sanofi S.A Anti-epileptic Drugs for Pediatrics Corporation Information
Table 79. Sanofi S.A Corporation Information
Table 80. Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 81. Sanofi S.A Main Product
Table 82. Sanofi S.A Recent Development
Table 83. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Corporation Information
Table 84. UCB Pharma Limited Corporation Information
Table 85. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 86. UCB Pharma Limited Main Product
Table 87. UCB Pharma Limited Recent Development
Table 88. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Corporation Information
Table 89. Sunovion Pharmaceuticals Limited Corporation Information
Table 90. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 91. Sunovion Pharmaceuticals Limited Main Product
Table 92. Sunovion Pharmaceuticals Limited Recent Development
Table 93. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Corporation Information
Table 94. Valeant Pharmaceuticals International, Inc Corporation Information
Table 95. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 96. Valeant Pharmaceuticals International, Inc Main Product
Table 97. Valeant Pharmaceuticals International, Inc Recent Development
Table 98. Zogenix Anti-epileptic Drugs for Pediatrics Corporation Information
Table 99. Zogenix Corporation Information
Table 100. Zogenix Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 101. Zogenix Main Product
Table 102. Zogenix Recent Development
Table 103. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Corporation Information
Table 104. GW Pharmaceuticals Corporation Information
Table 105. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 106. GW Pharmaceuticals Main Product
Table 107. GW Pharmaceuticals Recent Development
Table 108. Insys Anti-epileptic Drugs for Pediatrics Corporation Information
Table 109. Insys Corporation Information
Table 110. Insys Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 111. Insys Main Product
Table 112. Insys Recent Development
Table 113. Zynerba Anti-epileptic Drugs for Pediatrics Corporation Information
Table 114. Zynerba Corporation Information
Table 115. Zynerba Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 116. Zynerba Main Product
Table 117. Zynerba Recent Development
Table 118. Sales Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Anti-epileptic Drugs for Pediatrics Distributors List
Table 121. Anti-epileptic Drugs for Pediatrics Customers List
Table 122. Market Key Trends
Table 123. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 124. Key Challenges
Table 125. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Forecast by Type (2021-2026)
Table 126. Global Anti-epileptic Drugs for Pediatrics Sales Market Share Forecast by Type (2021-2026)
Table 127. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) Forecast by Type (2021-2026)
Table 128. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 129. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Forecast by Application (2021-2026)
Table 130. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) Forecast by Application (2021-2026)
Table 131. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Forecast by Region (2021-2026)
Table 132. Global Anti-epileptic Drugs for Pediatrics Sales Market Share Forecast by Region (2021-2026)
Table 133. Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 134. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share Forecast by Region (2021-2026)
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Anti-epileptic Drugs for Pediatrics
Figure 2. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type: 2020 VS 2026
Figure 3. 1st generation Product Picture
Figure 4. 2nd generation Product Picture
Figure 5. 3rd generation Product Picture
Figure 6. Global Anti-epileptic Drugs for Pediatrics Consumption Market Share by Application: 2020 VS 2026
Figure 7. Hospitals
Figure 8. Retail pharmacies
Figure 9. Online pharmacies
Figure 10. Global Anti-epileptic Drugs for Pediatrics Market Size 2015-2026 (US$ Million)
Figure 11. Global Anti-epileptic Drugs for Pediatrics Sales Capacity (K Units) (2015-2026)
Figure 12. Global Anti-epileptic Drugs for Pediatrics Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Anti-epileptic Drugs for Pediatrics Sales Share by Manufacturers in 2020
Figure 14. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers in 2019
Figure 15. The Global 5 and 10 Largest Players: Market Share by Anti-epileptic Drugs for Pediatrics Revenue in 2019
Figure 16. Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 17. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2015-2020)
Figure 18. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region in 2019
Figure 19. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2015-2020)
Figure 20. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region in 2019
Figure 21. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019
Figure 22. North America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019
Figure 23. U.S. Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 24. U.S. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 25. Canada Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 26. Canada Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 27. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019
Figure 28. Europe Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019
Figure 29. Germany Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 30. Germany Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 31. France Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 32. France Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 33. U.K. Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 34. U.K. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Italy Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 36. Italy Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Russia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 38. Russia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Region in 2019
Figure 40. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region in 2019
Figure 41. China Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 42. China Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Japan Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 44. Japan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. South Korea Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 46. South Korea Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. India Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 48. India Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Australia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 50. Australia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Taiwan Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 52. Taiwan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Indonesia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 54. Indonesia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Thailand Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 56. Thailand Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Malaysia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 58. Malaysia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Philippines Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 60. Philippines Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Vietnam Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 62. Vietnam Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019
Figure 64. Latin America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019
Figure 65. Mexico Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 66. Mexico Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Brazil Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 68. Brazil Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Argentina Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 70. Argentina Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019
Figure 72. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019
Figure 73. Turkey Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 74. Turkey Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Saudi Arabia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 76. Saudi Arabia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. U.A.E Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units)
Figure 78. U.A.E Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Sales Market Share of Anti-epileptic Drugs for Pediatrics by Type (2015-2020)
Figure 80. Sales Market Share of Anti-epileptic Drugs for Pediatrics by Type in 2019
Figure 81. Revenue Share of Anti-epileptic Drugs for Pediatrics by Type (2015-2020)
Figure 82. Revenue Market Share of Anti-epileptic Drugs for Pediatrics by Type in 2019
Figure 83. Global Anti-epileptic Drugs for Pediatrics Sales Growth by Type (2015-2020) (K Units)
Figure 84. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020)
Figure 85. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application in 2019
Figure 86. Global Revenue Share of Anti-epileptic Drugs for Pediatrics by Application (2015-2020)
Figure 87. Global Revenue Share of Anti-epileptic Drugs for Pediatrics by Application in 2020
Figure 88. Mylan N.V Total Revenue (US$ Million): 2019 Compared with 2018
Figure 89. Cephalon, Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Janssen Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Pfizer, Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Sanofi S.A Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. UCB Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Sunovion Pharmaceuticals Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. Valeant Pharmaceuticals International, Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. Zogenix Total Revenue (US$ Million): 2019 Compared with 2018
Figure 99. GW Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 100. Insys Total Revenue (US$ Million): 2019 Compared with 2018
Figure 101. Zynerba Total Revenue (US$ Million): 2019 Compared with 2018
Figure 102. Price Trend of Key Raw Materials
Figure 103. Manufacturing Cost Structure of Anti-epileptic Drugs for Pediatrics
Figure 104. Manufacturing Process Analysis of Anti-epileptic Drugs for Pediatrics
Figure 105. Anti-epileptic Drugs for Pediatrics Industrial Chain Analysis
Figure 106. Channels of Distribution
Figure 107. Distributors Profiles
Figure 108. Porter's Five Forces Analysis
Figure 109. North America Anti-epileptic Drugs for Pediatrics Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 110. North America Anti-epileptic Drugs for Pediatrics Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 111. Europe Anti-epileptic Drugs for Pediatrics Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 112. Europe Anti-epileptic Drugs for Pediatrics Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 113. Latin America Anti-epileptic Drugs for Pediatrics Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 114. Latin America Anti-epileptic Drugs for Pediatrics Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 115. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 116. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 117. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 118. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 119. Bottom-up and Top-down Approaches for This Report
Figure 120. Data Triangulation
Figure 121. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’